December 16, 2017 8:50 AM ET

Pharmaceuticals

Company Overview of Phrixus Pharmaceuticals, Inc.

Company Overview

Phrixus Pharmaceuticals, Inc. develops and commercializes pharmaceuticval s and therapies related to heart failure. The company develops Carmeseal, a therapy for the treatment of heart failure. Phrixus Pharmaceuticals, Inc. was incorporated in 2006 and is based in Ann Arbor, Michigan.

Building 520

2nd Floor

1600 Huron Parkway

Ann Arbor, MI 48109

United States

Founded in 2006

Phone:

734-926-0966

Key Executives for Phrixus Pharmaceuticals, Inc.

Director and Executive Officer
Executive Officer and Director
Compensation as of Fiscal Year 2017.

Phrixus Pharmaceuticals, Inc. Key Developments

Phrixus Pharmaceuticals, Inc. Announces Phase 2 Clinical Trial of Poloxamer 188 NF in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

Phrixus Pharmaceuticals, Inc. announced agreements with several DMD patient organizations and Cincinnati Children’s Hospital to conduct a first clinical trial of Carmeseal-MD™’s, active pharmaceutical ingredient Poloxamer 188 NF (P-188 NF), for the treatment of DMD in non-ambulatory patients. A number of endpoints will be evaluated including effects of P-188 NF on respiratory endpoints such as forced vital activity and on secondary endpoints related to cardiac and skeletal limb muscle performance. This single-center, open-label Phase 2 study will enroll 8 patients, non-ambulatory boys and young men with early heart failure and respiratory dysfunction on stable regimen of background therapies, including corticosteroids. Patients will be evaluated by cardiac MRI, pulmonary function testing and a number of upper body function tests, including performance of upper limb (PUL). Dosing will be for 52 weeks at 5 mg/Kg of P-188 NF, injected once-a-day subcutaneously, with drug product provided by the National Heart Lung and Blood Institute.

FDA allows Phrixus’s IND for Carmeseal-MD™ (P-188 NF) in Duchenne Muscular Dystrophy (DMD)

Phrixus Pharmaceuticals announced that FDA allowed Phrixus’s IND for Carmeseal-MD (P-188 NF) in Duchenne muscular dystrophy (DMD). The protocol that forms the basis of this IND includes a two-arm, randomized, double-blinded design with 120 patients in several centers in which one dose of P-188 NF will be evaluated against standard of care over 48 weeks. The primary endpoint will be forced vital capacity (FVC); a broad set of secondary endpoints will include cardiac endpoints and additional respiratory endpoints and measures of upper body strength in addition to safety measures. The IND-enabling studies were supported by the NIH’s National Heart, Lung and Blood Institute and by Coalition Duchenne.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Phrixus Pharmaceuticals, Inc., please visit www.phrixuspharmaceuticals.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.